A Phase 4 interventional study of Telithromycin in Bronchitis, Chronic, sponsored by Sanofi. Completed. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-02-17.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Non-inferiority efficacy of telithromycin versus azithromycin
268 studies on the registry are indexed under Bronchitis; 26 are open to participants now.
This study's enrollment of 668 is above the median of 120 across 184 interventional studies indexed under Bronchitis.
Browse Bronchitis studies →Sanofi is the lead sponsor of 1,508 studies on the registry; 90 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 118 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Principal efficacy criterion: clinical outcome - Main secondary efficacy criteria: - Bacteriological response at TOC visit; - Time to relapse up to 6 months after inclusion.
Time frame: At TOC visit (Day 17-Day 21).
No study locations are listed for this record.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi